EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Advances and Prospects in Pharmacotherapy for Graves’ Disease

Shujie Yu, Hongyan Wu

International Journal of Clinical Medicine · 2026 · 17 (03) · 95-106

DOI: 10.4236/ijcm.2026.173007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Medicine, 2026. Verfasst von Shujie Yu und 1 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To systematically review recent advances in the pharmacotherapy of Graves’ disease (GD) and provide evidence-based recommendations for individualized clinical management.

Methods

We conducted a comprehensive literature search of PubMed, Cochrane Library, and CNKI databases for studies published within the past ten years focusing on antithyroid drugs (ATDs), biologics, and small-molecule targeted therapies.

Results

Traditional ATDs remain first-line therapy for GD; however, relapse rates following discontinuation approach 50%. Novel targeted therapies—including anti-CD20 monoclonal antibodies (rituximab), anti-CD40 monoclonal antibodies (iscalimab), and neonatal Fc receptor (FcRn) antagonists—have demonstrated potential in reducing thyrotropin receptor antibody (TRAb) titers and improving remission rates in refractory GD. TSH receptor (TSHR) blocking antibodies and small-molecule antagonists represent promising etiological treatment strategies.

Conclusion

GD pharmacotherapy is transitioning from empirical immunosuppression to precision-targeted interventions. Future therapeutic paradigms should emphasize individualized treatment protocols and discontinuation strategies guided by dynamic TRAb monitoring.

Zitieren

APA

Yu, S., & Wu, H. (2026). Advances and Prospects in Pharmacotherapy for Graves’ Disease. International Journal of Clinical Medicine, 17(03), 95-106. https://doi.org/10.4236/ijcm.2026.173007

Vancouver

Yu S, Wu H. Advances and Prospects in Pharmacotherapy for Graves’ Disease. International Journal of Clinical Medicine. 2026;17(03):95-106. doi:10.4236/ijcm.2026.173007

BibTeX
@article{Yu2026,
  author = {Yu, Shujie and Wu, Hongyan},
  title = {Advances and Prospects in Pharmacotherapy for Graves’ Disease},
  journal = {International Journal of Clinical Medicine},
  year = {2026},
  volume = {17},
  number = {03},
  pages = {95--106},
  doi = {10.4236/ijcm.2026.173007}
}
Kostenlos starten →